Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy

Ophthalmology

Volumn 106, Issue 3, 1999, Pages 586-589

  Kotake, Satoshi ^a   Higashi, Kozue ^a   Yoshikawa, Koji ^a   Sasamoto, Yoichi ^a   Okamoto, Tamami ^a   Matsuda, Hidehiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; ATAXIA; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONVULSION; DYSARTHRIA; DYSMETRIA; FEMALE; FEVER; HEADACHE; HEMIPARESIS; HUMAN; MALE; NEUROTOXICITY; PARALYSIS; PRIORITY JOURNAL; VERTIGO;

EID: 0033504877     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90120-3     Document Type: Article

References (16)

1. Inaba G. Behçet's disease. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishers, 1989; v. 56, chap. 32.
2. Assaad-Khalil S, Abou-Seif M, Abou-Seif S, et al. Neurologic involvement in Behçet's disease: Clinical, genetic and computed tomographic study. In: Wechsler B, Godeau P, eds. Behçet's Disease: Proceedings of the 6th Int'l Conference on Behçet's Disease. Paris, France, 1993. Amsterdam; New York: Excerpta Medica, 1993;409-14 (Int'l. Congress Series; no. 1037).
3. Harada K, Tuboi E. Cyclosporin and Behçet's disease like syndrome. Ganka 1991;23:3343-6.
4. Pahlitzsch Th, Wyrobisch W, Kampe Ch. Therapie der okulären Form des Morbus Behçet mit Cyclosporin A [Eng. Abstr.]. Klin Monatsbl Augenheilkd 1990;196:466-9.
5. Mizushima Y. Recent research into Behçet's disease in Japan. Int J Tissue React 1988;10:59-65.
6. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1: 1093-6.
7. Kotake S, Furudate N, Sasamoto Y, et al. Clinical study on patients with Behçet's disease in Hokkaido. Ocular Immunol Inflamm 1995;3:237-41.
8. Inaba G. Clinical features of neuro-Behçet's syndrome. In: Lehner T, Barnes CG, eds. Recent Advances in Behçet's Disease. London; New York: Royal Society of Medicine Services, 1986:235-46 (Int'l. Congress and Symposium Series; no. 103).
9. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45: 953-1040.
10. Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 1984;38:34-7.
11. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995;45:1962-4.
12. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995;58:548-54.
13. Direskeneli H, Keser G, D'Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease. Clin Rheumatol 1995;14:55-61.
14. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115: 763-9.
15. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118:723-9.
16. Igarashi I, Ishigatsubo Y, Ohno S, et al. Central nervous system toxicity related to FK506 in patients with Behçet's disease. Ann Rheum Dis 1994;53:350-1.